Stopped: insufficient rate of accrual
The purpose of this study is to determine the most effective intraarticular steroid dose for the treatment of glenohumeral osteoarthritis. The investigators aim to randomize patients into low, medium, and high dose groups of injectable corticosteroids as these doses are typically used in the standard of care for our patients. To date there has been no study to evaluate which dose is most efficient with the fewest side effects for glenohumeral osteoarthritis. The investigators objective will be to provide ultrasound guided intraarticular glenohumeral injections of these randomized concentrations and to evaluate pain and function before and following injection with the Shoulder Pain and Disability Index (SPADI). The investigators hypothesize that the low dose steroid will provide equivalent improvement of the pain and function to the medium and high doses, while minimizing side effects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Overall SPADI Scores at Baseline Compared to 2,4, and 6 Months.
Timeframe: baseline, 2, 4, and 6 months. Baseline SPADI score was collected prior to injection.
Assess Reactions to the Steroid
Timeframe: baseline, 2, 4, and 6 months. Baseline data was collected at 2wks post injection phone call.